When it comes to Immunotherapy it's becoming one of the most prominent fields in Bio pharmanowadays, and if you're not familiar with that field it's the designed override of the immune system responses for the benefit of the patient because it's not able to detect the cancer affecting it, in this article we'll take a brief look at active T-cell therapy research.
Mainly active t-cell therapy is a form of passive immunotherapy that's carried out through the introduction of the immune system T cells that are then responsible to go about attacking cancerous cells.
How they usually work is that they're naturally present within the tissue and blood and their activation occurs whenever a pathogen presentsitself.
To be more specific, activation is undergone when the T cells surfacereceptors encounter antigen proteins that are foreign to the body, such could be immune cells or APCs short for antigen presenting cells, and in actuality both are actually present within normal and infected tissues called Tumor infiltrating lymphocytes that undergo activation when APCs are present like dendrites.
Now that we understand the basis through which this form of therapy works, we can now move on to knowing how it's possible to produce and obtain T cells that could target the cancerous tumors .
T cells that can target a specific tumor antigen could be actually removed from a cancerous tumor sample or it's possible to extract T cells from the blood of the patient.
After extraction is completed, then activation and growth of these cells is performed outside the body which is also called ex vivo.
Once they're properly activated and grown, they're once again re-introduced within the patient.
For activation to take place, a cancerous cell antigen could be presented to the T cell, or Gene therapy could be used.
Another approach that could be applied is to extract haploidentical T cells or NK cells from the healthy donor, how this can benefit the patient is that these cells don't allow graft-versus-host disease to occur, though a noted disadvantage is that the function of these cells is frequently impaired.
Now that we understand how it's possible to extract and activate them and make them work within the patient, let's take a look at the current progress in making this an approved therapy.
Despite many major advances in this type of research, there isn't any approved treatment as of yet.
It's noted though that several clinical trials in 2014 initially resulted in the complete remission of leukemia in some patients.
And thus this wraps up our quick look at adoptive T cell therapy and its connection to passive cancer immunotherapy, and how far it has reached in terms of workability.
Mainly active t-cell therapy is a form of passive immunotherapy that's carried out through the introduction of the immune system T cells that are then responsible to go about attacking cancerous cells.
How they usually work is that they're naturally present within the tissue and blood and their activation occurs whenever a pathogen presentsitself.
To be more specific, activation is undergone when the T cells surfacereceptors encounter antigen proteins that are foreign to the body, such could be immune cells or APCs short for antigen presenting cells, and in actuality both are actually present within normal and infected tissues called Tumor infiltrating lymphocytes that undergo activation when APCs are present like dendrites.
Now that we understand the basis through which this form of therapy works, we can now move on to knowing how it's possible to produce and obtain T cells that could target the cancerous tumors .
T cells that can target a specific tumor antigen could be actually removed from a cancerous tumor sample or it's possible to extract T cells from the blood of the patient.
After extraction is completed, then activation and growth of these cells is performed outside the body which is also called ex vivo.
Once they're properly activated and grown, they're once again re-introduced within the patient.
For activation to take place, a cancerous cell antigen could be presented to the T cell, or Gene therapy could be used.
Another approach that could be applied is to extract haploidentical T cells or NK cells from the healthy donor, how this can benefit the patient is that these cells don't allow graft-versus-host disease to occur, though a noted disadvantage is that the function of these cells is frequently impaired.
Now that we understand how it's possible to extract and activate them and make them work within the patient, let's take a look at the current progress in making this an approved therapy.
Despite many major advances in this type of research, there isn't any approved treatment as of yet.
It's noted though that several clinical trials in 2014 initially resulted in the complete remission of leukemia in some patients.
And thus this wraps up our quick look at adoptive T cell therapy and its connection to passive cancer immunotherapy, and how far it has reached in terms of workability.